key: cord-0898794-q3083hur
authors: Chioh, Florence WJ; Fong, Siew-Wai; Young, Barnaby E; Wu, Kan-Xing; Siau, Anthony; Krishnan, Shuba; Chan, Yi-Hao; Carissimo, Guillaume; Teo, Louis LY; Gao, Fei; Tan, Ru San; Zhong, Liang; Koh, Angela S; Tan, Seow-Yen; Tambyah, Paul A; Renia, Laurent; Ng, Lisa FP; Lye, David C; Cheung, Christine
title: Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation
date: 2021-03-23
journal: eLife
DOI: 10.7554/elife.64909
sha: bf61dfd4b676b044ee7c30b527f329dda71ed7cf
doc_id: 898794
cord_uid: q3083hur

Numerous reports of vascular events after an initial recovery from COVID-19 form our impetus to investigate the impact of COVID-19 on vascular health of recovered patients. We found elevated levels of circulating endothelial cells (CECs), a biomarker of vascular injury, in COVID-19 convalescents compared to healthy controls. In particular, those with pre-existing conditions (e.g., hypertension, diabetes) had more pronounced endothelial activation hallmarks than non-COVID-19 patients with matched cardiovascular risk. Several proinflammatory and activated T lymphocyte-associated cytokines sustained from acute infection to recovery phase, which correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction. Notably, we found higher frequency of effector T cells in our COVID-19 convalescents compared to healthy controls. The activation markers detected on CECs mapped to counter receptors found primarily on cytotoxic CD8(+) T cells, raising the possibility of cytotoxic effector cells targeting activated endothelial cells. Clinical trials in preventive therapy for post-COVID-19 vascular complications may be needed.

As of February 21, 2021, there have been more than 110 million confirmed cases and 2.4 million deaths from coronavirus disease 2019 . Many countries are facing multiple waves of resurgence upon reopening their economy, prompting new lockdown. Intensive ongoing research has shed light on the pathogenesis of COVID-19 and the extent of damages caused directly or indirectly by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conversely, the intermediate and long-term complications of COVID-19 remains unclear (del Rio et al., 2020) . While most infected people recover completely within a few weeks, a considerable proportion continue to experience symptoms after their initial recovery (Yelin et al., 2020) , similar to SARS survivors (Ngai et al., 2010) .

COVID-19 is mainly a respiratory infection. However, both autopsy findings and clinical observations have described vascular damages and thrombotic complications in a wide range of organs (Gupta et al., 2020; Price et al., 2020; Xu et al., 2020) . Endothelialitis may occur in multiple organs as a consequence of viral infection and overactive host immune response as T cell infiltration was observed in sites of endothelial damage of COVID-19 patients' tissues. Systematic evaluation of the long-term sequelae of COVID-19 is currently lacking. COVID-19 infection can cause extrapulmonary pathologies that persist after recovery such as cardiovascular events with ongoing myocardial inflammation (Puntmann et al., 2020) , acute ischemic or hemorrhagic stroke (Mao et al., 2020) , as well as liver injury, neurological deficits, and acute kidney injury necessitating dialysis (Gupta et al., 2020) . The thrombotic complications of COVID-19, such as pulmonary embolism may lead to lasting organ failure (Price et al., 2020) . Independent of acute respiratory distress syndrome, severe pneumonia has been consistently associated with augmented risk of cardiac impairment both during convalescence and in later years (Corrales-Medina et al., 2015) . We hypothesize that the risk of vascular complications in COVID-19 survivors will be higher, if compounded by a confluence of SARS-CoV-2mediated damages, proinflammatory cytokine overdrive, and comorbidities with hypertension and diabetes.

Circulating endothelial cells (CECs), dislodged from blood vessels as a consequence of vascular injury, constitute an ideal cell-based biomarker as it is indicative of in situ endothelial pathophysiology (Farinacci et al., 2019; Hill et al., 2003) . Although CECs are a rare population in peripheral blood, they reflect endothelial dysfunction from a variety of vascular disorders, including myocardial infarction, acute ischemic stroke, atherosclerosis, and vasculitis (Nadar et al., 2005; Schmidt et al., 2015) . In COVID-19, there are conflicting reports as to the frequency of CEC counts compared with healthy controls (Mancuso et al., 2020; Nizzoli et al., 2020) . This discrepancy may reflect disease severity as COVID-19 patients admitted to the intensive care unit (ICU) have a higher CEC count, suggesting more pronounced endothelial injury in severe COVID-19 (Guervilly et al., 2020) . Interestingly, among non-ICU patients, those with chronic kidney disease had significantly higher CEC counts, implying that patients with pre-existing conditions may be more susceptible to vascular damage (Guervilly et al., 2020) .

This study aims to understand the state of vascular health in convalescent COVID-19 patients and to evaluate subclinical endothelial dysfunction through the phenotyping of CECs.

To understand the intermediate consequence of COVID-19, we performed vascular phenotyping using CECs and endothelial activation markers as the cellular and molecular measures of endothelial dysfunction. Written informed consent was received from participants prior to inclusion in the PRO-TECT study (Young et al., 2020a,c) . All study groups were almost gender-balanced, with prior comorbidities and self-identified ethnicity/race as summarized in Table 1 . Convalescent COVID-19 patients who had no pneumonia throughout admission (mild), pneumonia without hypoxia (moderate), or pneumonia with hypoxia (desaturation to 94%) requiring supplemental oxygen (severe), and discharged after 15 days (median [interquartile range, IQR 11-26]) were screened for pre-existing cardiovascular risk factors. Among our selected convalescent COVID-19 patients (n = 30), half had at least one cardiovascular risk factor, including mainly hypertension, diabetes, and/or hyperlipidemia. They were benchmarked to healthy participants (n = 24) and non-COVID patients with matched cardiovascular risk factors (n = 20). More details on demographics are included in Table 1 .

There are two major types of blood endothelial cells (Hebbel, 2017) . CECs are shed from damaged vessels and constitute a cell-based biomarker for vascular dysfunction . On the other hand, endothelial progenitor cells (EPCs) originate from the bone marrow and are mobilized into the bloodstream in response to vascular injury (Ackermann et al., 2020a,bAckermann et al.,c; Li and Li, 2016; Mancuso et al., 2020) . Identification of the CEC population from individual peripheral blood mononuclear cells (PBMCs) samples was carried out with high stringency using a panel of established CEC immunophenotypic markers (Figure 1a) . We first gated for the CD45 À /CD31 + population to isolate CECs along with bone marrow-derived EPCs and platelets, while ruling out CD45 + leukocytes that also expressed the endothelial marker CD31 (PECAM1) (Duda et al., 2007) . This population was further subtyped based on the progenitor marker, CD133, to rule out EPCs. Finally, a nucleic acid stain was used to distinguish anucleate platelets from nucleated CECs, which were defined here by a combined immunophenotypic profile of CD45 À /CD31 + /CD133 À /DNA + (Burger and Touyz, 2012; Duda et al., 2007; Yu et al., 2013) . As a comparison, putative EPCs were identified by CD133 + /CD45 À /DNA + population (Ingram et al., 2004; Mancuso et al., 2020; Rafii and Lyden, 2003) . To further analyze endothelial cell activation, CECs were characterized for the expression of activation markers, namely, intercellular adhesion molecule 1 (ICAM1), P-selectin (SELP), and fractalkine (CX3CL1) (Figure 1a) , which are integral for the processes of leukocyte adhesion, platelet aggregation, and trans-endothelial migration, respectively (Goncharov et al., 2017; Johnson and Jackson, 2013) . We enumerated and compared the mean CEC and EPC numbers per million PBMCs between healthy participants, convalescent COVID-19 patients, convalescent COVID-19 patients with cardiovascular risks, and patients with cardiovascular risk but no history of COVID-19. The mean CEC counts were significantly increased in all the convalescent COVID-19 groups and non-COVID-19 cardiovascular risk group compared to the healthy participants, while no significant difference was noted for EPCs ( Figure 1b) . Between the two convalescent COVID-19 groups, patients with cardiovascular risk had higher mean CEC numbers (M = 153.75 ± 51.55) than patients without cardiovascular risk (M = 116.21 ± 28.17). These observations are consistent with our hypothesis that COVID-19 patients, especially those with pre-existing cardiovascular risk, may display persistent signs of vascular dysfunction even after recovery from COVID-19.

To ascertain the consequence of COVID-19 on endothelial dysfunction, we regrouped the convalescent COVID-19 patients by their disease severity during acute infection ( Figure 1c ). We found that both convalescent COVID-19 patients who recovered from moderate symptoms (p=0.0009) and non-COVID-19 patients with cardiovascular risks (p<0.0001) had significantly higher numbers of CECs than healthy controls. It was surprising that convalescent COVID-19 patients from severe symptoms did not result in significantly higher CEC counts, probably due to limited representations in our current sample pool. With regard to EPC counts, no significant difference was observed possibly due to the absence of recent adverse vascular events in our groups with cardiovascular risks. EPC levels are more likely to elevate immediately following thrombotic events when EPCs are mobilized from the bone marrow into the bloodstream to facilitate vascular repair (Massa et al., 2005; Shintani et al., 2001; Valgimigli et al., 2004; Yip et al., 2008) . Here, measurement of CECs seemed to be able to detect subclinical endothelial dysfunction. Collectively, Figure 1b and c demonstrate the potential impact of COVID-19 and cardiovascular risk factors on endothelial injury, as indicated by the elevated number of CECs in circulation.

We further performed molecular profiling of CECs for endothelial activation markers and used healthy participants as baseline. Our data revealed a significantly higher mean numbers of ICAM1 + CECs in convalescent COVID-19 with or without cardiovascular risk and non-COVID-19 cardiovascular risk groups ( Figure 1d ). Only convalescent COVID-19 patients with cardiovascular risk had a higher SELP + CEC count (p=0.0291), while a higher CX3CL1 + CEC count was found only in non-COVID-19 cardiovascular risk patients (p=0.0462). When we analyzed their endothelial activation hallmarks by disease severity (Figure 1e ), both convalescent COVID-19 patients who recovered from moderate symptoms (p=0.006) and non-COVID-19 patients with cardiovascular risks (p=0.0148) had significantly higher numbers of ICAM1 + CECs than healthy controls. We also observed a trend that convalescent COVID-19 patients who recovered from severe symptoms had the highest number of SELP + CECs, although insignificant. As seen in the spread of data in Figure 1d and e, large interindividual variations in CEC characteristics were expected and could obscure observations of statistically significant comparisons. To overcome this, we compared the proportion of patients with regard to the numbers of activation markers expressed by CECs in each group, and a Chi-squared goodness-of-fit test was carried out to assess if the percentages of patients were similar across the groups. We found a significant relationship between the number of endothelial activation markers expressed by CECs and the disease status of patients, Χ 2 (9, N = 64)=19.83, p=0.019 where convalescent COVID-19 patients compounded with cardiovascular risk had the most pronounced endothelial activation hallmarks (Figure 1f ), more than those having either a history of COVID-19 alone or cardiovascular risk without COVID-19. Conversely, COVID-19 severity did not render significantly different extent of endothelial activation hallmarks ( Figure 1g ). These findings demonstrate that COVID-19 may act in concert with comorbidities of hypertension and diabetes to intensify risks of future vascular complications due to elevated endothelial activation state.

Multiplex microbead-based immunoassay was performed to determine the cytokine levels in COVID-19 patient plasma during hospital admission and after discharge. To investigate the association between cytokine responses and cardiovascular risks, cytokine and chemokine levels were compared between COVID-19 patients with and without cardiovascular risk during the acute and convalescent phases of infection ( Figure 2a) . We found that COVID-19 patients with cardiovascular risk had lower levels of growth factors brain-derived neurotrophic factor (median concentration 22.70 vs. 38.57 pg/ mL, p=0.015), PDGF-BB (median concentration 31.08 vs. 62.51 pg/mL, p=0.023) and PIGF-1 (median concentration 30.69 vs. 1.49 pg/mL, p=0.040) compared to patients without cardiovascular risk at the early acute phase of infection (first plasma sample collected after hospital admission, at a median 10 days after symptom onset, IQR 7-15) ( Figure 2b ). These growth factors are known to promote vascular function (Alomari et al., 2015; Brown et al., 1995; Carmeliet et al., 2001) , and our observations suggest that the endothelial dysfunction underlying patients with cardiovascular risk may impede vascular repair following injury during the acute phase of virus infection. Interestingly, the plasma levels of proinflammatory IL-1b (median concentration 4.95 vs. 3.51 pg/mL, p=0.026), IL-17A (median concentration 3.12 vs. 0.09 pg/mL, p=0.003), IL-2 (median concentration 48.82 vs. 27.07 pg/mL, p=0.007), and RANTES (median concentration 105.00 vs. 72.47 pg/mL, p=0.037) were significantly higher in patients with cardiovascular risk than those without ( Figure 2b ) during the early convalescent phase (first plasma sample collected after hospital discharge, median 7 days post hospital discharge, IQR 3-12). Notably, the levels proinflammatory cytokines such as IL-1b, IL-17A, IL-2, and RANTES remained elevated in COVID-19 patients at the early convalescent phase, particularly in those with prior cardiovascular risk, compared to healthy controls ( Figure 2b ). Result from a simple linear regression analysis showed that age was significantly associated with the presence of cardiovascular risks in our COVID-19 patients. After adjustment for age by multiple linear regression analysis, levels of RANTES at the early convalescent phase was significantly associated with cardiovascular risks (Supplementary file 1).

To understand whether persistent immune activation may impact endothelial dysfunction, we performed correlation analysis of cytokine levels with the aforementioned CEC attributes. Interestingly, CEC attributes from convalescent patients without prior cardiovascular risk correlated significantly with a greater number of cytokines than those with cardiovascular risk (Figure 3a) . This may suggest that persistent cytokine production contributed primarily to endothelial injury (CEC counts) and activation hallmarks (CX3CL1 + and SELP + ) in convalescent patients without previously known risk factors. On the other hand, more pronounced endothelial injury and activation in those with cardiovascular risk would have been attributed to their pre-existing cardiovascular risk factors, on top of the aftermath of COVID-19. Among the positively correlated cytokines in the cardiovascular risk group (Figure 3a) , MIP-1a (CCL3) related to a chemoattractant for leukocytes, along with IL-17A (Williams et al., 2019) , IL-8 (Apostolakis et al., 2009) , and IL-18 (Gerdes et al., 2002) , known to evoke activation of endothelial cells during atherogenesis, may suggest chronic development of atherosclerotic plaques already in these individuals.

For the convalescent patients without prior risk factors, the measures of CEC attributes reflected greater sensitivity to cytokine-driven endothelial dysfunction that could signify a more direct consequence of COVID-19. Further protein-protein interaction network analyses with Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) highlighted the direct and indirect interactions between the significant cytokines and their functional associations with biological processes involved in inflammatory response, vasculature development, angiogenesis, leukocyte chemotaxis, B cell proliferation, and T cell activation (Figure 3b ). Among the positively correlated cytokines (Figure 3a) , we observed growth factors-associated tissue regeneration and remodeling, namely EGF, LIF, PDGF-BB, and PIGF-1 (PGF), indicating possibility of adaptive angiogenesis taking place as a response to preceding damages caused by viral infection and cytokine overdrive. IL-1RA, an IL-1 pathway inhibitor, could be an inflammation resolving mediator post infection. Conversely, IP-10 (CXCL10) is known to limit angiogenesis (Bodnar et al., 2006) . This collective turnover of endothelial cells during blood vessel remodeling may result in elevated number of CECs. A number of significantly correlated cytokines are chemokines known to induce endothelial activation and promote chemotaxis of leukocytes to vascular endothelium. Chemotactic factors such as IP-10 (CXCL10), CXCL12, and RANTES (CCL5) regulate adhesion and transmigration of T lymphocytes, monocytes, and/or neutrophils through endothelial barrier (Sokol and Luster, 2015) . Moreover, RANTES was specifically correlated with SELP + CEC (r = 0.5677, p=0.0295), indicating that activated plateletderived RANTES may work in concert with endothelial SELP to mediate platelet aggregation and trigger coagulation cascade. In partial correlation analyses, a majority of these CEC-cytokines correlations were sustained even after accounting for age (Supplementary file 1) .

Overall, CEC attributes of convalescent COVID-19 patients correlated with a vast majority of differentiation and activation factors associated with T cells and B cells (IL-4, IL-5, IL-7, IL-17A, IL-18, MIP-1a, and RANTES) (Turner et al., 2014) , implicating a broad adaptive immune response with endothelial dysfunction. Besides being a target of the immune mediators, we recognize that endothelial cells, once activated, could also be a source of these cytokines, which in turn could activate their immune counterparts.

Our ability to measure activation markers directly on CECs motivated us to better understand the receptor-receptor and chemokine-receptor interactions between activated endothelial cells with putative immune subpopulations in COVID-19. We performed data mining of published single-cell transcriptomic datasets on PBMCs from healthy participants, mild and severe COVID-19 patients (Wilk et al., 2020) , and COVID-19 patients with or without cardiovascular disease (Schulte-Schrepping et al., 2020) . Then, we re-analyzed the expressions of counter receptors (i.e., ITGAL, SELPLG, and CX3CR1) to our endothelial activation markers (i.e., ICAM1, SELP, and CX3CL1, respectively), in order to identify the potential immune interactors with activated endothelial cells. We found that those counter receptors were most pronouncedly expressed by CD8 + T cells, natural killer (NK) cells, and to some extent monocytes (Figure 4a and Figure 4-figure supplement 1) . In Wilk et al.'s dataset, the expression of CX3CR1 was intensified in mild and severe COVID-19 patients than healthy participants (Figure 4a) . The relationship between counter receptors expression and COVID-19 disease was even more marked in Schulte-Schrepping et al.'s dataset with a higher proportion of NK or both CD8 + and NK cells expressing all three counter receptors found in mild and severe COVID-19 samples, respectively, regardless of comorbidity with cardiovascular disease (Figure 4-figure supplement 1) . As the presence of those counter receptors generally marks cytotoxic effector lymphocytes in peripheral blood (Nishimura et al., 2002) , we correspondingly found that CD8 + T cells and NK cells were the major cytotoxic populations expressing perforin and granzymes (Figure 4b) , especially in COVID-19 patients (Figure 4-figure supplement 1) . We hypothesize that persistent cytokine production activates endothelial cells in convalescent COVID-19 patient, which may promote interactions with cytotoxic effector cells. Therefore, we analyzed T cell features by immunophenotyping in our cohort (Carissimo et al., 2020) and found that convalescent COVID-19 patients, in particular those with underlying cardiovascular risk, had significantly higher frequencies of effector CD8 + and CD4 + T cells (EM), and central memory CD8 + T cells (CD8 CM) than healthy controls (Figure 5a) , while there were no notable differences across the groups for absolute numbers of circulating CD8 + /CD4 + T cells. There is a possibility that individuals recovered from COVID-19 could be susceptible to vascular injury due to effector T cell cytotoxicity ( Figure 5b) . However, the results herein remain associative, and further experiments are required to establish cytotoxicity-induced endothelial injury in COVID-19 convalescents.

The rapid rise of COVID-19 'long-haulers' with lingering symptoms post-infection or recovered individuals who suffer from sudden cardiovascular events, would continue to place tremendous strain on our healthcare systems. About 2.5% of convalescent COVID-19 patients are found with thrombosis (including arterial and venous events), 30 days post discharge (Patell et al., 2020) . As endothelial dysfunction often precedes serious thrombotic complications and ischemic damages to organs, we performed vascular phenotyping through analysis of CECs in convalescent COVID-19 patients. CECs are dysfunctional endothelial cells shed from damaged vessels, hence a surrogate marker of vascular injury (Farinacci et al., 2019; Hill et al., 2003) . Our findings reveal that COVID-19 convalescents had significantly higher CEC count than non-COVID-19 healthy participants. Beyond enumeration of CECs, we further measured ICAM1, SELP, and CX3CL1 on CECs, expressions of which would suggest proinflammatory and procoagulant state of the endothelial cells originating from sites of vascular injury. In comparison with non-COVID-19 patients with cardiovascular risk (i.e., hypertension, diabetes, hyperlipidemia), the compounded effects of COVID-19 and prior cardiovascular risk factors rendered the most pronounced endothelial activation markers in COVID-19 convalescents. Activated endothelial cells are likely to release cytokines, which trigger extrinsic coagulation pathway (Coccheri, 2020), suggesting that recovered individuals may be susceptible to risk of thrombotic complications.

The sequence of events leading to post-COVID-19 complication has not been fully elucidated, but likely a vicious cycle caused by vascular leakage, activation of coagulation pathway, and inflammation (Teuwen et al., 2020) . In this study, our cytokine profiling confirmed that cytokine production remained heightened post-infection. Of interest, the CEC attributes of our COVID-19 convalescents correlated significantly with a number of proinflammatory cytokines. We also found significantly higher proportions of effector CD8 + and CD4 + T cells in our COVID-19 convalescents, especially those with pre-existing cardiovascular risk, than healthy participants. Collectively, these suggest that prolonged overactive state of the immune system could be implicated with endothelial dysfunction. Published immunophenotyping studies on recovered COVID-19 patients are emerging. In many COVID-19 convalescents, broad CD8 + T-cell response against multiple SARS-CoV-2 proteins mediated by effector and memory T cell populations were detected, suggesting a key role for T cells in protective immunity in recovered patients (Dan et al., 2021; Grifoni et al., 2020; Oxford Immunology Network Covid-19 Response T cell Consortium et al., 2020) . It was reported that majority of these SARS-CoV-2 reactive T cells in COVID-19 convalescents had phenotypic markers of TEMRA (Dan et al., 2021) known to be more differentiated and cytotoxic in nature. Here, our analysis of published scRNA-seq datasets demonstrated that CD8 + T cells in COVID-19 patients were associated with cytotoxic genes, as well as receptors that might potentially interact with counter receptors/ligands on activated endothelial cells. This led us to hypothesize that activated endothelial cells in COVID-19 convalescents could become a target of cytotoxic effector T lymphocytes. Endothelial injury could result in vascular permeability, further exposing tissue factor from underneath, which predisposes to risk of blood clotting (van Hinsbergh, 2012) .

Immune cell-mediated endothelial injury has been observed in other viral infections, including Ebola, human cytomegalovirus infection, and malaria, where T cells recruited to infected site by inflammation could induce apoptosis of infected endothelial cells, causing vascular leakage (Claser et al., 2019; van de Berg et al., 2012; Wolf et al., 2015; Yang et al., 2000) . Likewise, in non-infectious diseases such as acute coronary syndrome and systemic sclerosis, cytotoxic CD4 + T cells were capable of causing damages to endothelial cells (Maehara et al., 2020; Nakajima et al., 2002) . It is also possible that some endothelial cells affected by SARS-CoV-2 infection had elicited pattern recognition receptors such as toll-like receptors, activating interferon pathway and inflammatory cytokine production that persist to convalescent phase. Antigen-experienced T cells preferentially adhere to activated endothelial cells and undergo transendothelial migration (Carman and Martinelli, 2015; Marelli-Berg et al., 2004) , triggering vascular remodeling due to endothelial damage (Cuttica et al., 2011) . Therefore, we postulate that activated and infected endothelial cells could be susceptible to direct cytotoxic T cell-mediated killing due to persistent immune activation in COVID-19 convalescents. However, in vitro experimentation with activated endothelial and immune cells is needed to confirm this hypothesis. How persistent cytokine response and effector T cell populations could translate into endothelial dysfunction during convalescence warrant further functional investigation.

We are mindful of the limitations with this current study. First, we noted our small sample size and other unmeasured confounding conditions, besides the current determinants of cardiovascular risks, which could contribute to some heterogeneity in our CEC and immune profiling. Second, convalescent blood samples were collected at various time points due to logistical constraints in recalling recovered patients on the same day post-infection. Finally, to understand post-COVID-19 complications, long-term phenotyping of vascular functions and immune profiles of convalescent patients is still lacking due to short-term horizons from when these individuals were first infected. There is a critical need to monitor prospective cohorts of recovered individuals in order to establish the full spectrum of clinical courses of complications. Global efforts in this aspect are evident and are underway.

Hematologic assessment (i.e., thrombin generation, platelet activation studies, von Willebrand factor) is commonly performed to help manage convalescent patients who have been re-admitted for acute thrombosis. It would be valuable to risk stratify convalescent patients before adverse events happen. Our profiling of CECs may serve as a form of vascular surveillance to complement hematologic assessment in identifying early molecular and endothelial changes in high-risk individuals. Analysis of CECs may detect subclinical changes in the vasculatures and be able to provide accurate and easily transferable endpoints in clinical assessment.

In summary, managing the aftermath of COVID-19 is an imperative. Endothelial instability may be a key mechanism underpinning the development of post-infection vascular complications. Clinical trials in preventive therapy for vascular complications may be needed. Analysis and visualization of scRNA-seq data Study design, participants, and clinical data collection of convalescent COVID-19 patients Convalescent COVID-19 individuals were recalled from the PROTECT study, which is a prospective observational cohort study at three public hospitals in Singapore (the National Centre for Infectious Diseases, National University Hospital, and Changi General Hospital). Written informed consent was obtained from participants who provided clinical data and biological samples. Study protocols were approved by ethics committees of the National Healthcare Group (2012/00917).

The electronic medical records of patients enrolled in the PROTECT study were reviewed and their data entered onto a standardized collection form adapted from the International Severe Acute Respiratory and Emerging Infection Consortium's case record form for emerging severe acute respiratory infections. Serial blood samples were collected during hospitalization and post-discharge. Blood samples were processed as previously reported (Singapore 2019 Novel Coronavirus Outbreak Research Team et al., 2020b Young et al., 2020c) . PBMCs were isolated from whole blood collected in Cell Preparation Tubes (BD, #362761) for downstream CEC characterization. Plasma samples were separately stored for subsequent cytokine profiling.

Study design, participants, and clinical data collection of healthy participants and non-COVID-19 patients with cardiovascular risk factors

Healthy participants and non-COVID-19 patients with cardiovascular risk factors were obtained from the Cardiac Ageing Study (Koh et al., 2018) , which is a prospective observational cohort study performed at the National Heart Centre Singapore. The current study sample consisted of healthy participants who had no known cardiovascular disease or cerebrovascular disease or cancer. We included non-COVID-19 patients with cardiovascular risk factors for this comparison. All participants were examined and interviewed on one study visit by trained study coordinators. Participants completed a standardized questionnaire that included medical history and coronary risk factors. Sinus rhythm status was ascertained by resting electrocardiogram. Clinical data were obtained on the same day as biological sample collection.

Antecubital venous blood samples were taken from participants on the same day. After collection, the blood samples were immediately placed on ice for transportation and were processed within 6 hr to obtain buffy coat samples, which were subsequently cryopreserved.

Study protocols were approved by ethics committees of the Nanyang Technological University Singapore (IRB-2020-09-011). PBMC samples were washed with Dulbecco's phosphate-buffered saline (DPBS; Hyclone, SH30028.02) + 1% BSA (Bovine Serum Albumin, Hyclone, SH30574.02), and then resuspended in 100 mL of DPBS + 1% BSA for antibody staining (Antibody panel in this section). Staining was carried out in the dark for 10 min at room temperature, followed by 20 min at 4˚C on an analog tube rotator. After staining, cells were rinsed and resuspended in DPBS + 1% BSA for downstream flow cytometry analysis. Flow cytometry was performed using BD LSRFortessa X-20 (BD Bioscience, San Jose, California, United States ) and data acquisition was performed on FACSDiva software, version 8.0.1 (BD Bioscience, San Jose, California, United States ). Spectral overlap between INDO-1, APC, PE, PE-Cy7, AF488, and BV711 channels was calculated automatically by the FACSDiva software after measuring single-color compensation controls from pooled PBMCs. Optimal compensation was achieved using compensation control beads (anti-mouse Ig, k/ negative control compensation particles set, 552843) together with corresponding conjugated antibodies. Acquired data were analyzed using FlowJo software, version 10.7.1. Analysis of each patient typically included between 50,000 and 2,00,000 PBMCs depending on sample availabilities. CECs were detected by a combined immunophenotypic profile of CD45 À /CD31 + /CD133 À /DNA + and were further characterized for the expressions of ICAM1, SELP, and CX3CL1. Attributes such as CECs or "activated" CECs were represented as cells per million of PBMCs in Figure 1 . 

Single cell transcriptomic datasets published by Wilk et al., 2020 (Figure 4 ) were re-analyzed using the cellxgene platform (https://cellxgene.cziscience.com/d/Single_cell_atlas_of_peripheral_immu-ne_response_to_SARS_CoV_2_infection-25.cxg/). Briefly, the uniform manifold approximation and projection (UMAP) visualization was annotated using the metadata included using the "cell_type_fine" taxonomy. The expression data were obtained by interrogating the individual expression of the genes in the UMAP (CX3CR1, ITGAL, and SELPLG) or across the various immune population included in the "cell_type_fine" taxonomy (PRF1, GZMA, and GZMB). The single cell datasets published by Schulte-Schrepping et al., 2020 were re-analyzed as described in the Figure 4 -figure supplement 1.

Plasma samples were treated with 1% Triton X-100 solvent-detergent mix for virus inactivation (Darnell and Taylor, 2006) . Cytokine levels in COVID-19 patient plasma across different acute and convalescent time points were measured with the Luminex assay using the cytokine/chemokine/ growth factor 45-plex Human ProcartaPlex Panel 1 (ThermoFisher Scientific). The Cytokine/Chemokine/Growth Factor 45-plex Human ProcartaPlex Panelone panel included granulocyte-macrophage colony-stimulating factor (GM-CSF), epidermal growth factor (EGF), brain-derived neurotropic factor, beta-nerve growth factor (bNGF), basic fibroblast growth factor (FGF-2), hepatocyte growth factor (HGF), monocyte chemoattractant protein (MCP) 1, macrophage inflammatory protein (MIP) 1a, MIP-1b, RANTES (regulated on activation, normal T cell expressed and secreted), chemokine (C-X-C motif) ligand (CXCL) 1 (GRO-a), stromal cell-derived factor 1 (SDF-1a), interferon (IFN) gammainduced protein 10 (IP-10), eotaxin, IFN-a, IFN-g, interleukin (IL) IL-1a, IL-1b, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, leukemia inhibitory factor (LIF), stem cell factor (SCF), tumor necrosis factor (TNF)-a and -b, vascular endothelial growth factors A and D (VEGF-A, VEGF-D), platelet derived growth factor (PDGF-BB), and placental growth factor (PLGF-1). Standards and plasma from COVID-19 patients and healthy controls were incubated with fluorescent-coded magnetic beads pre-coated with respective antibodies in a black 96-well clear-bottom plate overnight at 4˚C. After incubation, plates were washed five times with wash buffer (PBS with 1% BSA [Capricorn Scientific GmbH, Ebsdorfergrund, Germany]) and 0.01% Tween (Promega Corporation, Madison, Wisconsin, United States). Sample-antibodybead complexes were incubated with Biotinylated detection antibodies for 1 hr and washed five times with wash buffer. Subsequently, Streptavidin-PE was added and incubated for another 30 min. Plates were washed five times again before sample-antibody-bead complexes were re-suspended in sheath fluid for acquisition on the FLEXMAP 3D (Luminex) using xPONENT 4.0 (Luminex) software.

Internal control samples were included in each Luminex assays to remove any potential plate effects. Readouts of these samples were then used to normalize the assayed plates. A correction factor was obtained from the differences observed across the multiple assays and this correction factor was then used to normalize all the samples. Standard curves were generated with a 5-PL (5-parameter logistic) algorithm, reporting values for mean florescence intensity (MFI) and concentration data. The concentrations were logarithmically transformed to ensure normality. Patient samples with a concentration out of measurement range were assigned the value of the logarithmic transformation of the limit of quantification. Data analysis was done with Bio-Plex Manager 6.1.1 software.

Whole blood was stained with antibodies for 20 min in the dark at room temperature, as reported previously (Carissimo et al., 2020) . Samples were then supplemented with 0.5 mL of 1.2Â BD FACS lysing solution (BD 349202). Final 1Â concentration taking into account volume in tube before addition is~1% formaldehyde to fix viruses as well as lyse the red blood cells. Samples were vortexed and incubated for 10 min at room temperature. About 500 mL of PBS (Gibco, #10010-031) was added to wash the samples and spun at 300 g for 5 min. Washing step of samples were repeated with 1 mL of PBS. Samples were then transferred to polystyrene FACS tubes containing 10 mL (10,800 beads) of CountBright Absolute Counting Beads (Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts, United States, #36950). Samples were then acquired using BD LSRII five laser configuration using automatic compensations. For analysis of flow cytometry data, FlowJo version 10.6.1 was used for analysis of flow cytometry data. T cell populations were identified by previously reported gating strategies (Carissimo et al., 2020) .

Due to inter-individual heterogeneities of flow cytometry and cytokine data, nonparametric tests of association were preferentially used throughout this study unless otherwise stated. For flow cytometry data on CEC attributes, statistical differences between groups were calculated using Kruskal-Wallis test with Dunn's multiple comparison post-test. Significant p values (<0.05) were indicated on the graphs directly. To assess for differences in the frequencies of patients with CECs expressing endothelial activation markers, ICAM1, SELP, or CX3CL1 and the cumulative frequencies for all markers, the number of patients per group were summarized in contingency tables. These were then analyzed with Chi-squared goodness-of-fit test with expected values generated from the data using GraphPad Prism, version 8.3.1. For the cytokine analysis, Mann-Whitney U tests were used to discern the differences in cytokine levels between the patients with or without cardiovascular risk factors. A multiple linear regression analysis was conducted to examine the association between plasma cytokines and the presence of cardiovascular risks in COVID-19 patients after adjustment for age. Heatmap and scatter plots were generated using GraphPad Prism version 8. Concentrations of immune mediators were scaled between 0 and 1 for visualization in the heatmap. Protein-protein interaction networks of the CECassociated cytokines were predicted and illustrated with Search Tool for the Retrieval of Interacting Genes/Proteins database (STRING) (version 11.0; available at: https://string-db.org). All the interactions between cytokines were derived from high-throughput laboratory experiments and previous knowledge in curated databases at a confidence threshold of 0.4.

For correlative study between CEC attributes and cytokine levels, we selected non-parametric Spearman correlation with no assumption regarding value distribution. Non-linear regression and Spearman's rank correlation coefficients were calculated to access associations between the level of serum cytokines and CEC attributes for convalescent COVID-19 patients with and without cardiovascular risk factors. The level of statistical significance was set at two-tailed test with p values <0.05 to detect any significant associations between specific cytokines and CEC attributes. Statistical analyses for this correlative study were performed using GraphPad Prism software, version 8.3.1. To address potential age-related contributions to the correlations observed between CEC and plasma cytokines in Figure 3 , non-parametric partial correlation coefficients based on Spearman's rank correlations were determined for the identified correlated variables while controlling for age. The R package 'ppcor' was used to compute the coefficients, p values and test statistics in Supplementary File. (Kim, 2015) .

This study was approved by the Local Ethics Committee of the National Healthcare Group (2012/ 00917) and Nanyang Technological University Singapore Institutional Review Board (IRB-2020-09-011).

Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing -review and editing

Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing -original draft, Writing -review and editing

Resources, Data curation, Formal analysis, Funding acquisition, Writing -review and editing; Kan-Xing Wu, Formal analysis, Methodology, Writing -original draft, Writing -review and editing

Formal analysis, Visualization, Writing -original draft, Writing -review and editing

Data curation, Formal analysis

Ru San Tan, Liang Zhong, Resources, Funding acquisition, Writing -review and editing

Resources, Data curation, Funding acquisition, Writing -review and editing; Seow-Yen Tan

Conceptualization, Supervision, Funding acquisition, Writing -review and editing

Conceptualization, Resources, Supervision, Funding acquisition, Writing -review and editing

Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing -original draft, Project administration, Writing -review and editing Author ORCIDs Yi

Laurent Renia

Ethics Human subjects: This study was approved by the Local Ethics Committee of the National Healthcare Group (2012/00917) and Nanyang Technological University Singapore Institutional Review Board

Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow

Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Vascular function and brain-derived neurotrophic factor: the functional capacity factor

Interleukin 8 and cardiovascular disease

A randomized, phase 1, placebo-controlled trial of APG-157 in oral Cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes

Circulating endothelial cells biomarker of vascular disease

IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain

Platelet-derived growth factor BB induces functional vascular anastomoses in vivo

Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells

Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19

T Lymphocyte-Endothelial interactions: emerging understanding of trafficking and Antigen-Specific immunity

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

Lung endothelial cell antigen crosspresentation to CD8 + T cells drives malaria-associated lung injury

COVID-19: the crucial role of blood coagulation and fibrinolysis

Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease

Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products

Long-term health consequences of COVID-19

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

Circulating endothelial cells as biomarker for cardiovascular diseases

Metabolic pathway analysis and molecular docking analysis for identification of putative drug targets in Toxoplasma gondii: novel approach

Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages

Markers and biomarkers of endothelium: when something is rotten in the state

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Circulating endothelial cells as a marker of endothelial injury in severe COVID -19

Extrapulmonary manifestations of COVID-19

Blood endothelial cells: utility from ambiguity

Circulating endothelial progenitor cells, vascular function, and cardiovascular risk

Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood

The chemokine CX3CL1 promotes trafficking of dendritic cells through inflamed lymphatics

Ppcor: an R package for a fast calculation to Semi-partial correlation coefficients

Dissecting clinical and metabolomics associations of left atrial phasic function by cardiac magnetic resonance feature tracking

Endothelial progenitor cells accelerate the resolution of deep vein thrombosis

Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis

Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo

Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction

Circulating endothelial cells in acute ischaemic stroke

T-cell-mediated lysis of endothelial cells in acute coronary syndromes

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+ /granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression

Circulating endothelial cells in COVID-19

Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Postdischarge thrombosis and hemorrhage in patients with COVID-19

Thrombosis and COVID-19 pneumonia: the clot thickens!

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

Circulating endothelial cells in coronary artery disease and acute coronary syndrome

Severe COVID-19 is marked by a dysregulated myeloid cell compartment

Mobilization of endothelial progenitor cells in patients with acute myocardial infarction

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

The chemokine system in innate immunity

COVID-19: the vasculature unleashed

Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease

CD34 + and endothelial progenitor cells in patients with various degrees of congestive heart failure

Cytomegalovirus-induced effector T cells cause endothelial cell damage

Endothelium-role in regulation of coagulation and inflammation

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Cytokine circuits in cardiovascular disease

Severe ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Identification of the ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury

Long-term consequences of COVID-19: research needs

Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

Viral dynamics and immune correlates of COVID-19 disease severity

Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies

We thank all clinical and nursing staff who provided care for the patients; staff in the Singapore Infectious Disease Clinical Research Network and Infectious Disease Research and Training Office of the National Centre for Infectious Diseases for coordinating patient recruitment. We also wish to thank Ms Siti Naqiah Amrun, Ms Rhonda Sin-Ling Chee, Mr Nicholas Kim-Wah Yeo, Mr Anthony Torres-Ruesta, Drs Chek Meng Poh, Cheryl Yi-Pin Lee, Matthew Tay, and Zi-Wei Chang from the Singapore Immunology Network (SIgN), for their help in isolating PBMCs and plasma fractions from the blood of COVID-19 patients. We are also grateful to Dr Danielle Anderson and her team at Duke-NUS, for their technical assistance in virus inactivation procedures with Triton-X-100; Dr Olaf Rö tzschke, Dr Bernett Lee, Wilson How, and Norman Leo Fernandez from the Singapore Immunology Network (SIgN) Multiplex Analysis of Proteins (MAP) platform, for their assistance in running multiplex microbead-based immunoassay. We also thank Ms Manisha Cooray, Dr Chun-Yi Ng, and Ms Natalie Yeo for their technical help during experimental optimization.

Competing interests Barnaby E Young: Barnaby E. Young declares no direct competing interests with this work, but has received honorarium outside this work from Sanfoi and Roche. Paul A Tambyah: Paul A. Tambyah declares no direct competing interests with this work but has received research support outside this work from Roche, Sanofi-Pasteur, Johnson and Johnson, AJ Biologicals and Shionogi. The other authors declare that no competing interests exist.